ArticleCancers2022
Postoperative Recurrences in Patients Operated for Pheochromocytomas and Paragangliomas: New Data Supporting Lifelong Surveillance.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Large asymptomatic pheochromocytoma with incidental metastatic midgut carcinoid tumor.JCEM case reports · 2026Article
- A case of perioperative and intraoperative management of a rare vaginal paraganglioma.Gynecologic oncology reports · 2026Article
- Sulfasalazine-Induced Urinary Normetanephrine Elevation Mimicking Recurrent Phaeochromocytoma-A Case Report.Case reports in endocrinology · 2026Article
- Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report.Therapeutic advances in endocrinology and metabolism · 2026Article
- Proteinuria as an Unusual Presentation of Pheochromocytoma in Pediatric Patient With Single Kidney.Case reports in pediatrics · 2026Article
- Article
- Late-Onset Bone Metastasis 46 Years After Initial Surgery for Pheochromocytoma: A Case Report.IJU case reports · 2025Article
- Rapid generation of a sdhb loss-of-function zebrafish model for secreting pheochromocytomas and paragangliomas.NPJ genomic medicine · 2025Article
- Surgical Management of Paraganglioma of the Organ of Zuckerkandl with Combined Resection of the Aorta and Inferior Vena Cava with Bifurcation: A Case Report.Vascular specialist international · 2025Article
- Multifactorial analysis and construction of a nomogram model for postoperative recurrence of glomus jugulare tumor.Frontiers in oncology · 2025Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Microsurgery in carotid body paraganglioma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024Article
- Pediatric malignant pheochromocytoma with atypical presentation as vision changes, lung metastasis, and recurrence: a case report.Journal of medical case reports · 2024Article
- Article
- Targeted metabolomics detects a putatively diagnostic signature in plasma and dried blood spots from head and neck paraganglioma patients.Oncogenesis · 2023Article
- Metastatic sporadic paraganglioma with EWSR1::CREM gene fusion: A unique molecular profile that expands the phenotypic diversity of the molecular landscape of the EWSR1::CREM gene fusion positive tumors.Genes, chromosomes & cancer · 2023Article
- Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.The Journal of clinical endocrinology and metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
At least 10% of pheochromocytomas (PHEOs) and paragangliomas (PGLs) (PPGLs) may recur after the initial surgery. Guidelines recommend annual screening for recurrence in non-metastatic tumors for at least 10 years after the initial surgical resection and lifelong screening in high-risk patients. However, recent data suggest that a shorter follow-up might be appropriate. We performed a retrospective analysis on patients with PPGLs who had local and/or metastatic recurrences between 1995 and 2020 in our center. Data were available for 39 cases of recurrence (69.2% female) including 20 PHEOs (51.3%) and 19 PGLs (48.7%) (13 head and neck (HNPGL) and 6 thoracoabdominal (TAPGL)). The overall average delay of recurrence was 116.6 months (14-584 months) or 9.7 years and the median was 71 months or 5.9 years. One-third of the cohort had a recurrence more than 10 years after the initial surgery (10-48.7 years). The average tumor size at initial diagnosis was 8.2 cm for PHEOs, 2.7 cm for HNPGLs, and 9.6 cm for TAPGLs. Interestingly, 17.6% of PHEOs were under 5 cm at the initial diagnosis. Metastatic recurrence was identified in 75% of PHEOs, 15.4% of HNPGLs, and 66.7% of TAPGLs. Finally, 12/23 (52.2%) patients with recurrence who underwent genetic testing carried a germline mutation. Overall, the safest option remains a lifelong follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.